Clinical Trial

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

Study acronym: ESCC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-13.
Trial Details
NCT Number NCT06601309
Lead Sponsor Fujian Medical University Union Hospital
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 90 participants
Start Date 2024-07-11
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-15